What Plasbumin Treats: Main Uses and Benefits

Plasbumin (Human Albumin) is generally used in clinical settings where supportive symptom management is appropriate in situations involving heightened systemic burden. Its general therapeutic purpose is to provide supportive assistance for conditions characterized by systemic imbalance.

The medication is commonly used to help with symptoms related to systemic imbalance, including those linked to fluid volume and low protein levels.

Stabilization in Acute Circulatory Deficits

The medication is commonly used to address symptoms related to systemic imbalance stemming from a significant deficit in circulating blood volume, such as hypovolemia associated with major trauma, extensive blood loss, or severe burns. This application is highly relevant when supportive symptom management is appropriate to assist with maintaining stability during acute or disruptive episodes. The primary benefit is that it provides supportive relief when symptoms interfere with routine activities and may assist with maintaining functional stability and managing symptoms that create noticeable physiological strain.

Managing Fluid Imbalance and Supportive Care

Plasbumin is relevant in conditions characterized by periods of heightened symptoms related to severe protein deficiency (hypoalbuminemia), such as those seen in acute liver failure or nephrotic syndrome. It is applied in settings marked by temporary physiological imbalance where fluid has inappropriately shifted out of the blood vessels. The therapeutic benefit is that it contributes to easing the overall symptom load by managing symptoms that interfere with daily comfort, which supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Circulatory Stress Plasbumin is commonly used in acute care to manage symptoms related to significant fluid volume loss and low plasma protein, which helps support the patient’s general well-being during symptomatic periods.

Plasbumin (Human Albumin) is subject to specific regulatory rules defining patient eligibility. These rules are based on a combination of absolute prohibitions, conditions that pose special risk, and age-related data limitations.

Contraindications (Who Must Not Use)

Use is absolutely contraindicated in individuals with a history of hypersensitivity or allergic reactions to any albumin preparation or its excipients. It is also prohibited for patients with severe anemia or cardiac failure who have a normal or increased circulating blood volume, due to the documented risk of cardiovascular overload.

Populations Requiring Conditional Use

Regulatory labels require special caution when administering Plasbumin in patients with certain conditions where the risk of volume expansion (hypervolemia) is high. Examples include decompensated cardiac insufficiency, hypertension, pulmonary edema, esophageal varices, and renal/post-renal anuria.

Age-Related Eligibility

• Pediatric Use: For many formulations, safety and effectiveness have not been established in dedicated pediatric studies. Use in children and infants should be reserved for situations where it is clearly needed.
• Older Adults: Clinical trials did not include sufficient subjects aged 65 and older to determine if their response differs from younger adults.
• Pregnancy/Lactation: Use during pregnancy (Category C) or breastfeeding is conditional, recommended only if clearly needed, due to the lack of established human data.

The regulatory documentation for Plasbumin (Human Albumin) indicates that its official interaction profile is characterized primarily by physical and chemical compatibility restrictions necessary for intravenous administration, rather than classical systemic drug-drug interactions. Regulatory bodies report that no specific metabolic or pharmacokinetic interactions with other medicinal products are known.

Prohibited Co-Administration and Diluents

Specific restrictions prohibit the physical mixing of Plasbumin with certain medicinal and non-medicinal substances in the intravenous line. The product must not be mixed with solutions containing protein hydrolysates or amino acid solutions due to formal chemical incompatibility. A critical, mandatory restriction governs the preparation process: Plasbumin must not be diluted with sterile water for injection. This constraint is imposed by regulatory labeling, as dilution with sterile water substantially reduces the solution's tonicity, posing a significant risk of hemolysis in recipients. Furthermore, solutions containing alcohol are prohibited from being mixed with Plasbumin.

Compatible Combinations

In defining the complete interaction profile, regulatory documentation affirms the compatibility of Plasbumin with several necessary medical fluids. The product is explicitly suitable for co-administration with whole blood and packed red cells, as well as with standard carbohydrate and electrolyte solutions intended for intravenous infusion.

How Plasbumin Works

Plasbumin, a human albumin solution, functions by modulating two primary physiological roles of native albumin: colloid osmotic pressure and molecular transport.

The primary mechanism involves the contribution of exogenous albumin to the overall plasma colloid osmotic pressure (COP). Albumin is the major determinant of this pressure within the vascular compartment. The resultant increased oncotic gradient across the capillary wall dictates the distribution of fluid, causing a net flux of water from the interstitial space into the circulation. This action sustains and influences intravascular fluid volume.

Furthermore, albumin acts as a significant non-specific carrier protein in the bloodstream. It facilitates the reversible, non-covalent binding and transport of various molecules that are otherwise poorly soluble in water, including fatty acids, steroid hormones, trace metals, and unconjugated bilirubin. This binding capacity also influences the circulating bioavailability and distribution of these molecular species.

Plasbumin is provided as a sterile solution for intravenous infusion and must be administered strictly through the venous system under professional supervision. The medication is available in several concentrations, including 5%, 20%, and 25% solutions.

The total amount used is highly variable and calculated based on the specific clinical situation, but the maximum daily dose is limited to 2 grams of albumin per kilogram of body weight.

---

Dosing Regimens and Ranges

Standard administration parameters are utilized for various clinical scenarios. For instance, in adults experiencing acute hypovolemia, the initial dose is typically 25 grams of Human Albumin, and this dose may be repeated after 15 to 30 minutes if necessary. For large volume paracentesis, the typical dose administered is 8 grams of albumin for every 1000 mL of ascitic fluid removed. For pediatric patients, the dose is determined using a calculation of 0.5 to 1 gram per kilogram of body weight.

---

Preparation and Administration Conditions

Specific preparation and administration conditions are followed for this therapy. The solution may be administered undiluted or diluted only with 0.9% Sodium Chloride or 5% Dextrose in Water. It is strictly prohibited to dilute the solution with Sterile Water for Injection due to the risk of hemolysis. The rate of infusion is also governed by the patient’s condition; in non-emergency situations, the 25% solution generally should not exceed 1 mL per minute. The prepared solution must be used within four hours of opening the container.

Plasbumin, a solution containing human albumin, is primarily used to restore and maintain circulating blood volume and manage low levels of albumin in the blood (hypoalbuminemia).

Clinical research focuses on the properties of albumin as a plasma volume expander and its role in maintaining colloid osmotic pressure. Studies have explored its use in critical conditions, including hypovolemic shock, severe burns, and complications associated with acute liver disease.

Key Clinical Findings

Clinical trials have evaluated the utility of human albumin solutions in various settings. Specifically, randomized controlled trials (RCTs) and meta-analyses have investigated the following:

• Volume Expansion: Research supports the use of Plasbumin and other human albumin solutions for stabilizing circulation and correcting volume deficit in patients with hypovolemia (low blood volume) due to trauma or surgery.
• Liver Cirrhosis: Studies have explored the effects of albumin infusion in patients with decompensated cirrhosis, particularly those with associated complications like spontaneous bacterial peritonitis (SBP) and ascites (fluid accumulation in the abdomen). Some trials indicate that albumin may be associated with a reduced incidence of acute kidney injury (AKI) in patients with SBP, though findings regarding overall survival in sepsis and septic shock remain debated and complex.
• Septic Shock: Large-scale systematic reviews of RCTs examining the use of human albumin for septic patients have produced mixed results, with some subgroup analyses suggesting a potential survival benefit when a concentrated albumin solution is used in patients with septic shock.

Safety Data from Research

The tolerability profile of the drug was assessed across multiple trials. Common adverse events were reported in the study participants. Adverse events, including those considered serious, were documented in the trial reports, highlighting the need for careful patient monitoring.

Common questions about Plasbumin (FAQ)

Q: How quickly does Plasbumin start to have an effect after it's given?

Plasbumin works by drawing fluid from the body's tissues back into the circulation to increase blood volume. Official product information indicates that the concentrated (25%) solution is described as capable of achieving this effect within about 15 minutes of administration, particularly in patients who have adequate body hydration.

Q: How long does the effect of Plasbumin usually last in the body?

The length of time the volume expansion effect lasts depends on the patient's underlying condition and fluid status. In individuals with low blood volume, this effect may persist for many hours. The protein itself (Human Albumin) has a long life in the body, with a circulating half-life generally reported as 15 to 20 days.

Q: Why do people sometimes say Plasbumin is a 'volume expander'?

Official documents classify the product as a plasma volume expander and a colloid solution. This terminology is used because its main role is to increase the volume of fluid circulating in the blood vessels, supporting blood pressure and circulation.

Q: What are the most common things people feel after they receive Plasbumin?

The official safety documents list common adverse effects experienced by patients. These include flushing (a feeling of warmth or redness, especially on the face and neck), nausea, and hives (urticaria). These effects are generally described in official documents as transient.

Q: Does Plasbumin have to be given in the hospital, or can it be done elsewhere?

Plasbumin is provided as a sterile solution that must be administered strictly through the venous system. It is administered under professional supervision and must be given by a healthcare professional.

Q: What if I'm allergic to something? Is there a high risk of reaction to Plasbumin?

The product is contraindicated (must not be used) in individuals who have a known history of hypersensitivity or allergic reaction to any albumin preparation or its ingredients. All patients are monitored during infusion for any signs of an immediate or severe allergic reaction.

Q: What is the official term for the type of shock Plasbumin is used for?

Regulatory documents indicate that one of the primary uses for Plasbumin is the Emergency Treatment of Hypovolemic Shock. This is a type of shock that occurs due to severe blood or fluid loss, resulting in very low circulating blood volume.

Q: Can a person become dependent on Plasbumin if they receive it often?

The product is not classified by regulatory bodies as having a potential for abuse or dependency, as it is a natural protein replacement.

Q: Is it common to feel flushed or warm while receiving the infusion?

Yes, flushing (a feeling of warmth or redness of the face, neck, or chest) is officially listed as a common adverse reaction that is sometimes associated with receiving the infusion.

Q: What kind of monitoring is done while a person is receiving Plasbumin?

Regulatory documents require careful monitoring of the patient's hemodynamic response and vital signs, such as blood pressure and pulse rate. This monitoring is done to guard against the possibility of circulatory overload (hypervolemia).

Q: How do doctors decide on the amount of Plasbumin to give?

Official guidance states the amount and rate of administration are adapted to the response and clinical needs of the patient. Decisions are guided by the patient's clinical condition, their body weight, and laboratory values such as serum albumin levels.

Q: Is it normal for my urine output to change after receiving Plasbumin?

Since the medication is designed to affect fluid balance and increase blood volume, changes in the body's fluid levels can result in changes to urine output. Monitoring urine output is a standard part of patient assessment during treatment.

Q: Why is it important to check blood pressure while getting Plasbumin?

It is important to check blood pressure because of the risk of circulatory overload (hypervolemia) due to the drug’s volume-expanding effect. Close monitoring is required to mitigate this risk.

Q: Can elderly patients use Plasbumin with the same expectations as younger adults?

Official labeling notes that dedicated clinical trials did not include sufficient subjects aged 65 and older to definitively determine if their response differs from younger adults. Due to limited data, official labeling suggests special caution is warranted for this population.

Q: Is there a difference in how Plasbumin is used in severe burns compared to trauma?

Regulatory documents indicate a difference in the timing of use. For severe burn patients, albumin is generally used after the initial 24-hour period to maintain plasma oncotic pressure, which is a timing difference from its use in acute trauma or shock.

Q: Is Plasbumin the same thing as just a blood transfusion?

Plasbumin is classified as a plasma substitute and a blood derivative, not a whole blood transfusion or packed red cells. Official regulatory documents note that it is compatible with co-administration alongside whole blood and packed red cells.

Q: What exactly is the difference between Plasbumin and other albumin products?

Plasbumin is a specific brand name for Human Albumin, USP, a protein derived from human plasma. While regulatory documents confirm that all Human Albumin products are sourced and stabilized similarly, they do not compare specific commercial brands like Plasbumin to others.

Q: Can Plasbumin be given to children or infants?

Official labeling states that the safety and effectiveness have not been definitively established in the pediatric population. However, it is sometimes used in children and infants when deemed clearly needed, as specific pediatric dosing guidance exists.

Q: Is Plasbumin safe for people who have kidney problems?

Official warnings require special caution for patients with certain kidney conditions, such as anuria, due to the drug's volume-expanding properties. Careful monitoring is required to mitigate the risk of circulatory overload.

Q: Are there different concentrations of Plasbumin, and what do they mean?

Plasbumin is available in 5%, 20%, and 25% concentrations. The 5% solution is described as iso-oncotic (similar fluid-pulling power to blood plasma), while the 25% solution is hyperoncotic (higher concentration). The higher concentration is often chosen to treat protein deficits.

Q: Can Plasbumin cause or contribute to swelling (edema)?

Safety constraints warn that the drug can lead to hypervolaemia (excessive blood volume) or pulmonary edema (fluid swelling in the lungs) if administered too rapidly or to a patient with cardiac risk. Careful monitoring is required to mitigate this risk.

Q: How does the manufacturing process ensure Plasbumin is safe from viruses?

Regulatory documents confirm the product is derived from human plasma and is heat-treated at 60 C for 10 hours. This is an established method to reduce the risk of transmitting viruses, including those that cause hepatitis. The manufacturing process also includes steps to remove other infectious agents.

How to Store and Dispose of Plasbumin

Plasbumin must be stored strictly according to the official label to maintain its stability. The required storage temperatures vary by concentration:

• Plasbumin-25: Store below 30 C (86 F).
• Plasbumin-5: Store between 2 C and 25 C (36 F and 77 F).

Do not freeze the solution, and protect it from light by storing it in its original container. The solution is for single-use only and should be administered immediately after the container is opened, as it contains no preservatives. Visually inspect the solution; do not use it if it is cloudy or contains particles.

Keep the product out of the sight and reach of children. Unused solution and waste material must be discarded in accordance with local requirements, not via household waste or wastewater.